Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
4(50%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_1
1
13%
Ph phase_2
3
38%
Ph phase_3
4
50%

Phase Distribution

1

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
4(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

8

all time

Status Distribution
Active(4)
Completed(4)

Detailed Status

Completed4
Active, not recruiting2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 23 (37.5%)
Phase 34 (50.0%)

Trials by Status

active_not_recruiting225%
completed450%
recruiting225%

Recent Activity

4 active trials
Showing 5 of 8
recruitingphase_3

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07449936
recruitingphase_3

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07449923
active_not_recruitingphase_3

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

NCT06668064
active_not_recruitingphase_3

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

NCT06683742
completedphase_2

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

NCT05381948
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07449936Phase 3

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Recruiting
NCT07449923Phase 3

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Recruiting
NCT06668064Phase 3

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

Active Not Recruiting
NCT06683742Phase 3

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

Active Not Recruiting
NCT05381948Phase 2

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

Completed
NCT05383209Phase 2

Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

Completed
NCT06099184Phase 2

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

Completed
NCT04747197Phase 1

First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8